SCHEMBL4799566

SCHEMBL4799566

Cc1ccccc1NS(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
SLC40A1 Q9NP59 3/20 0.58
GPR27 Q9NS67 1/20 0.56
TSHR P16473 3/20 0.53
MCL1 Q07820 2/20 0.53
HPGD P15428 1/20 0.53
ITGA1 P56199 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
EDNRA P25101 2/20 0.52
MAPK1 P28482 1/20 0.52
NPC1 O15118 1/20 0.51
EDNRB P24530 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
ALOX12 P18054 1/20 0.50
NLRP1 Q9C000 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7588364 0.89 SLC40A1 (0.63) SLC40A1TSHRMCL1HPGDITGA1
SCHEMBL4799558 0.82 SLC40A1 (0.56) SLC40A1TSHRMCL1HPGDITGA1
SCHEMBL7577319 0.81 SLC40A1 (0.63) SLC40A1TSHRMCL1HPGDITGA1
SCHEMBL13852847 0.81 ACLY (0.53) SLC40A1TSHRMCL1HPGDEDNRA
SCHEMBL7571597 0.79 SLC40A1 (0.64) ALDH1A1SLC40A1TSHRMCL1HPGD
SCHEMBL13853043 0.79 MCL1 (0.50) SLC40A1TSHRMCL1HPGDEDNRA
SCHEMBL28274758 0.79 ALDH1A1 (0.52) ALDH1A1GPR27TSHRHPGDMEN1
SCHEMBL23141245 0.78 ACLY (0.60) ALDH1A1SLC40A1HPGDITGA1MEN1
SCHEMBL31261221 0.78 ACLY (0.60) ALDH1A1SLC40A1HPGDITGA1MEN1
SCHEMBL4650351 0.78 TRPV4 (0.51) SLC40A1TSHRMCL1HPGDEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR ALDH1A1 2177/4885SLC40A1 3794/4885GPR27 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.